THNR - ETF AI Analysis
Top Page
Amplify Weight Loss Drug & Treatment ETF (THNR)
Rating:61Neutral
Price Target:―
Positive Factors
Exposure to Leading Drug Makers
The ETF holds several major pharmaceutical companies involved in weight-loss and treatment drugs, giving investors access to key players in this growing area.
Mix of Strong and Improving Holdings
Some top positions, such as Innovent Biologics, Arrowhead Pharmaceuticals, Amgen, AstraZeneca, and Pfizer, have shown strong or improving performance, helping offset weaker names in the portfolio.
Global Health Care Reach
While most holdings are U.S.-based, the fund also invests in companies from Hong Kong and Japan, adding some international diversification within the health care theme.
Negative Factors
High Sector Concentration
With nearly all assets in health care, the ETF is heavily exposed to industry-specific risks like regulatory changes, drug trial setbacks, or pricing pressures.
Weak Recent Performance
The fund’s year-to-date and recent three-month returns have been negative, reflecting pressure on many of its holdings in the short term.
Notable Weakness in Largest Holdings
Several of the biggest positions, including Novo Nordisk, Eli Lilly, Regeneron, Chugai Pharmaceutical, and Roche, have shown weak performance so far this year, which can weigh on overall fund results.
THNR vs. SPDR S&P 500 ETF (SPY)
AUM4.51M
RegionDeveloped Markets
Expense Ratio0.59%
Beta0.67
IssuerAmplify
Inception DateMay 21, 2024
Dividend Yield1.57%
Asset ClassEquity
Index TrackedVettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,558
30 Day Avg. Volume1,943
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
32.42Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
THNR Summary
The Amplify Weight Loss Drug & Treatment ETF (THNR) tracks the VettaFi Weight Loss Drug & Treatment Index and focuses on health care companies working on weight loss drugs and related treatments. It mainly holds pharmaceutical and biotech firms, including well-known names like Novo Nordisk and Eli Lilly, which are leaders in new obesity and diabetes medicines. Investors might consider this ETF if they want targeted growth potential from advances in weight loss treatments instead of buying single drug company stocks. However, it is highly concentrated in health care and can go up and down sharply based on drug trial results, regulations, and overall market swings.
How much will it cost me?The Amplify Weight Loss Drug & Treatment ETF (THNR) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise required to select investments.
What would affect this ETF?The Amplify Weight Loss Drug & Treatment ETF (THNR) could benefit from growing global awareness of obesity-related health issues and increased demand for innovative weight loss treatments, especially as its top holdings include major pharmaceutical companies like Eli Lilly and Novo Nordisk, which are leaders in this space. However, the ETF may face challenges from regulatory hurdles, competition in drug development, or economic downturns that could reduce consumer spending on health care solutions. Additionally, its heavy reliance on the health care sector makes it vulnerable to sector-specific risks, such as changes in government policies or patent expirations.
THNR Top 10 Holdings
This ETF is tightly focused on weight-loss drugs and treatments, with big pharma heavyweights Novo Nordisk and Eli Lilly setting much of the tone as they continue to climb, giving the fund a solid core in developed markets. On the faster-growth side, Hims & Hers and Arrowhead are sprinting higher, adding extra fuel but also a bit more volatility. Viking Therapeutics is more of a mixed story, while names like Regeneron and AstraZeneca have been losing steam lately, acting as a mild drag on overall performance.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 9.96% | $447.87K | $221.88B | -28.72% | 73 Outperform | |
| Eli Lilly & Co | 9.10% | $409.09K | $1.14T | 58.88% | 72 Outperform | |
| Hims & Hers Health | 5.74% | $258.08K | $8.52B | -20.94% | 68 Neutral | |
| Scholar Rock Holding | 5.53% | $248.66K | $6.58B | 65.19% | 50 Neutral | |
| AbbVie | 5.23% | $235.22K | $461.26B | 34.19% | 66 Neutral | |
| Innovent Biologics | 5.21% | $233.97K | HK$152.62B | 11.33% | 61 Neutral | |
| Viking Therapeutics | 5.12% | $229.96K | $4.35B | 28.22% | 53 Neutral | |
| Arrowhead Pharmaceuticals | 5.09% | $228.62K | $11.83B | 395.84% | 57 Neutral | |
| Regeneron | 4.96% | $223.11K | $68.59B | 23.46% | 78 Outperform | |
| AstraZeneca | 4.96% | $223.06K | $300.37B | 37.99% | 80 Outperform |
THNR Technical Analysis
Positive
―
Price Trends
24.72
Positive
24.82
Positive
24.72
Positive
Market Momentum
0.53
Negative
66.16
Neutral
82.11
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For THNR, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 25.07, equal to the 50-day MA of 24.72, and equal to the 200-day MA of 24.72, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 66.16 is Neutral, neither overbought nor oversold. The STOCH value of 82.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for THNR.
THNR Peer Comparison
Comparison Results
Performance Comparison
THNR
Amplify Weight Loss Drug & Treatment ETF
26.32
3.58
15.74%
AGNG
Global X Aging Population ETF
―
―
―
FDIQ
Invesco Bloomberg Financial Data Providers ETF
―
―
―
TINY
ProShares Nanotechnology ETF
―
―
―
WISE
Themes Generative Artificial Intelligence ETF
―
―
―
IVEP
Dan IVES Wedbush AI Power & Infrastructure ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents